Selective Rather Than Routine Histopathological Examination Following Appendectomy and Cholecystectomy (FANCY)
Selective Rather Than Routine Histopathological Examination Following Appendectomy and Cholecystectomy; the FANCY Study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Amsterdam-Zuidoost, Netherlands, 1105 AZ
- Academic Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients scheduled to undergo an appendectomy or cholecystectomy in the elective or non-elective setting.
Exclusion Criteria:
- Primary indication for surgery: strong suspicion or proven malignancy in the appendix or gallbladder.
- Appendix or gallbladder removed as part of more extensive surgery, so-called incidental appendectomies or cholecystectomies.
- Patients included in the ACCURE trial (effect of appendectomy on ulcerative colitis).
- The presence of a gallbladder polyp of >10 mm on preoperative imaging.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients who underwent an appendectomy
Patients of all ages who underwent an appendectomy in the elective or non-elective setting.
|
The removed appendix will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen.
The appendix will not be opened.
The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination.
Subsequently, all specimens will be sent for histopathological examination.
Histopathological examination will be conducted according to the local protocol.
In case of a neoplasm of the appendix, the treatment strategy is discussed and decided by the local multidisciplinary team.
If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
|
|
Patients who underwent a cholecystectomy
Patients of all ages who underwent a cholecystectomy in the elective or non-elective setting.
|
The removed gallbladder will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen.
The gallbladder is opened in its length, without cutting the cystic duct, and is inspected and palpated.
The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination.
Subsequently, all specimens will be sent for histopathological examination.
Histopathological examination will be conducted according to the local protocol.
In case of a neoplasm of the gallbladder, the treatment strategy is discussed and decided by the local multidisciplinary team.
If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Unnoticed neoplasms requiring additional therapy benefitting the patient
Time Frame: 3 months
|
Number of patients per 1000 examined appendices/gallbladders with a neoplasm requiring additional therapy benefitting the patient that would have been unnoticed in the policy of selective histopathological examination.
|
3 months
|
|
Costs
Time Frame: 3 months
|
Costs of the policy with selective and with routine histopathological examination of the appendix/gallbladder.
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Malignancies
Time Frame: 2 weeks
|
Incidence of malignancies in resected appendices and gallbladders
|
2 weeks
|
|
Unnoticed malignancies
Time Frame: 2 weeks
|
Incidence of unnoticed malignancies in resected appendices and gallbladders
|
2 weeks
|
|
Malignancies requiring more extensive resection or other additional treatment
Time Frame: 3 months
|
Incidence of malignancies in resected appendices and gallbladders that subsequently require more extensive resection or other additional treatment.
|
3 months
|
|
Benefit of additional resection
Time Frame: 2 weeks
|
Remaining tumour tissue and/or positive lymph nodes in re-resection specimen
|
2 weeks
|
|
Harm of additional resection
Time Frame: 1 month
|
Incidence of postoperative complications
|
1 month
|
|
Other aberrant findings
Time Frame: 2 weeks
|
Incidence of other aberrant findings as parasite infections, endometriosis, granulomatosis and benign neoplasms.
|
2 weeks
|
|
Other aberrant findings requiring additional therapy
Time Frame: 3 months
|
Incidence of other aberrant findings as parasite infections, endometriosis, granulomatosis and benign neoplasms that require additional therapy.
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Willem Bemelman, Professor, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Gallbladder Diseases
- Biliary Tract Diseases
- Cecal Diseases
- Biliary Tract Neoplasms
- Cecal Neoplasms
- Neoplasms
- Gallbladder Neoplasms
- Appendiceal Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- W17_328
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.